Mindbio Therapeutics CEO Issues Letter To Shareholders
Mindbio Therapeutics CEO Issues Letter To Shareholders
Mindbio治療公司CEO向股東發出信函
Dear Shareholders,
親愛的股東：
We are delighted to provide an update on progress at MindBio, as we head into the second half of 2024 and continue with dosing in multiple Phase 2B clinical trials and we advance the Company closer towards its commercialisation objective.
我們很高興地向您提供MindBio在2024年下半年的進展情況，同時在多個20億期的臨床試驗中進行給藥，讓公司更接近商業化目標。
The Company is pleased to report on its two currently dosing Phase 2B clinical trials which include assessing MB22001, MindBio's lead candidate drug in treating the following conditions:
公司很高興地報告其兩個目前進行第20億期臨床試驗的情況，這兩個試驗包括評估MindBio的主要候選藥物MB22001治療以下疾病的情況：
MindBio Leads Global Public Companies in Non-hallucinogenic Psychedelic Clinical Trials
MindBio在非幻覺熱帶靈與臨床試驗中的領先全球公開公司
MindBio is the only publicly listed company in the world specializing in a scalable psychedelic microdosing treatment model that is sub-hallucinogenic...
MindBio是全球唯一專注於可擴展的微量劑...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間